American Society of Hirudotherapy

Early venous congestion after diep flap breast reconstruction: case report of a successful management

Case report published in Acta Biomed (2022)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportClinical TrialsBaccarani A et al. · Acta bio-medica : Atenei Parmensis, 2022

Abstract

More than 250 000 women estimated to be diagnosed with breast cancer in the USA every year. Mastectomy is primary treatment for more than a third of those with early-stage disease. Most of the patients undergoing mastectomy receive breast reconstruction. A number of. Surgical techniques have been described to reconstruct the breast. With autologous tissue breast reconstruction, the plastic surgeon uses patient's own tissues, taken from a different part of the body where there is an excess of fat and skin. Deep inferior epigastric perforator (DIEP) flap is the autologous breast reconstruction technique of choice in our department due to long lasting results, low donor site morbidity and positive patient reported outcomes have been described.   Case Report: We present the case of a 42-year-old woman who underwent neoadjuvant chemotherapy followed by left breast simple mastectomy, axillary lymph-nodes dissection and later adjuvant radiation therapy (RT). After conclusion of RT a DIEP flap breast reconstruction was performed. Nine-hours after the operation, signs of acute venous congestion were noted. The venous congestion was treated by a combined surgical and medical approach based on pedicle discharge and ICU resuscitation protocol. After take back surgery, the patient was tightly monitored in the intensive care unit where intravenous heparin infusion and leech therapy were performed for 2 days. Flap congestion resolved completely, and the patient was discharged.   Conclusions: Venous congestion is very difficult to treat due to its potential multifactorial nature. The most important step is to recognize this kind of emergency because irreversible microvascular damages will develop in 6-8 hours. Because of multiple causes of venous congestion a timely multidisciplinary approach is mandatory, to maximize flap salvage and success rates.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsAdultBreast NeoplasmsFemaleHumansHyperemiaMammaplastyMastectomyPerforator Flap

Summary

42-year-old woman with DIEP flap breast reconstruction post-RT developed acute venous congestion 9 hours postop; managed with surgical pedicle discharge, heparin infusion and 2 days of leech therapy with complete flap survival.

Why This Matters for Hirudotherapy

This case report describes a 42-year-old woman who developed acute venous congestion nine hours after DIEP-flap breast reconstruction and was managed with a combined surgical and medical approach, including intravenous heparin infusion and leech therapy for two days in the ICU, after which the flap congestion resolved completely and she was discharged. It is directly relevant to hirudotherapy as a documented clinical instance of medicinal leeches used as part of flap-salvage decongestion, and it underscores the authors' point that venous congestion must be recognized and treated within the 6-8 hour window before irreversible microvascular damage occurs. As a single-patient case report combining several interventions, it cannot isolate the contribution of leeches or establish efficacy; it is anecdotal support for the established salvage role of leech therapy, not comparative evidence.

Citation

Early venous congestion after diep flap breast reconstruction: case report of a successful management.

Baccarani A et al. · Acta bio-medica : Atenei Parmensis, 2022

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.